Preparative method of R-(-)-ibuprofen by diastereomer crystallization
Archives of Pharmacal Research, ISSN: 0253-6269, Vol: 29, Issue: 1, Page: 108-111
2006
- 17Citations
- 7Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations17
- Citation Indexes17
- 17
- CrossRef12
- Captures7
- Readers7
Article Description
The economic and effective method for preparation of R-(-)-ibuprofen by diastereomer crystallization was developed. R-(-)-ibuprofen was resolved from racemic ibuprofen by forming R-(-)-ibuprofen-R-(+)-α-methylbenzylamine diastereomeric salt with R-(+)-α-methylbenzylamine and crystallization. The purity of R-(-)-ibuprofen-R-(+)-α-methylbenzylamine diastereomeric salt was tested and confirmed using HPLC and H-NMR method. The pure diastereomeric salt collected from repeated recrystallization was further fractionated by liquid-liquid extraction to the pure enantiomer without racemization. R-(-)-ibuprofen was recovered producing overall yield of 2.4% with the purity more than 99.97%.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=33144474880&origin=inward; http://dx.doi.org/10.1007/bf02977477; http://www.ncbi.nlm.nih.gov/pubmed/16491852; http://link.springer.com/10.1007/BF02977477; http://www.springerlink.com/index/pdf/10.1007/BF02977477; https://dx.doi.org/10.1007/bf02977477; https://link.springer.com/article/10.1007/BF02977477; http://www.springerlink.com/index/10.1007/BF02977477
Springer Nature
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know